Indication prioritization for pre-clinical asset with novel mechanism of action

The internal development leadership team of the Nasdaq-listed biotechnology company, Morphic Therapeutics, sought support in the clinical development planning and indication prioritization for a pre-clinical asset with a novel mechanism of action.